Larimar Therapeutics GAAP EPS of -$0.61 misses by $0.21
Source: SeekingAlpha
2025-11-05 12:28:51 ET
More on Larimar Therapeutics
- Larimar Therapeutics, Inc. (LRMR) Discusses On The Nomlabofusp Program For The Treatment Of Friedreich's Ataxia Conference Call (Transcript)
- Seeking Alpha’s Quant Rating on Larimar Therapeutics
- Historical earnings data for Larimar Therapeutics
- Financial information for Larimar Therapeutics
Read the full article on Seeking Alpha
For further details see:
Larimar Therapeutics GAAP EPS of -$0.61 misses by $0.21
Larimar Therapeutics Inc.
NASDAQ: LRMR
LRMR Trading
-7.36% G/L:
$4.595 Last:
1,914,421 Volume:
$4.87 Open:
LRMR Latest News
March 04, 2026 04:05:00 pm
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
February 25, 2026 08:59:46 pm
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
February 25, 2026 04:01:00 pm
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
February 24, 2026 07:56:05 pm
$38M Defense Backlog vs. $6M Market Cap, Breakthrough Biotech Data, and the Quantum Security Land Grab
LRMR Stock Data
$285,016,005
38,430,086
1.32%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Bala Cynwyd
